-$0.51 EPS Expected for Calithera Biosciences Inc (NASDAQ:CALA) This Quarter

Analysts expect Calithera Biosciences Inc (NASDAQ:CALA) to post earnings of ($0.51) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Calithera Biosciences’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.36). Calithera Biosciences reported earnings of ($0.52) per share during the same quarter last year, which indicates a positive year over year growth rate of 1.9%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Calithera Biosciences will report full year earnings of ($1.97) per share for the current year, with EPS estimates ranging from ($2.69) to ($1.54). For the next financial year, analysts forecast that the firm will report earnings of ($1.81) per share, with EPS estimates ranging from ($2.74) to ($1.25). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.03).

CALA has been the topic of a number of research reports. William Blair reiterated a “buy” rating on shares of Calithera Biosciences in a research report on Friday, June 21st. Citigroup set a $8.00 target price on shares of Calithera Biosciences and gave the company a “hold” rating in a research report on Friday. Finally, ValuEngine upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

Shares of Calithera Biosciences stock traded down $0.02 during trading on Tuesday, reaching $3.89. 5,873 shares of the company traded hands, compared to its average volume of 317,645. The company has a quick ratio of 6.75, a current ratio of 6.75 and a debt-to-equity ratio of 0.08. Calithera Biosciences has a 1-year low of $3.43 and a 1-year high of $6.90. The company has a 50 day moving average price of $4.10. The company has a market cap of $142.05 million, a price-to-earnings ratio of -2.61 and a beta of 1.86.

In other Calithera Biosciences news, insider Susan Molineaux acquired 51,600 shares of the stock in a transaction on Tuesday, June 25th. The shares were purchased at an average price of $3.88 per share, for a total transaction of $200,208.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.20% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sofinnova Investments Inc. purchased a new position in shares of Calithera Biosciences in the second quarter worth about $2,066,000. Monashee Investment Management LLC acquired a new stake in Calithera Biosciences in the second quarter valued at approximately $1,170,000. Renaissance Technologies LLC boosted its stake in shares of Calithera Biosciences by 53.0% in the second quarter. Renaissance Technologies LLC now owns 750,198 shares of the biotechnology company’s stock worth $2,926,000 after acquiring an additional 260,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Calithera Biosciences by 25.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,244,046 shares of the biotechnology company’s stock worth $4,988,000 after acquiring an additional 256,222 shares during the last quarter. Finally, Federated Investors Inc. PA boosted its stake in shares of Calithera Biosciences by 6.2% in the first quarter. Federated Investors Inc. PA now owns 3,767,763 shares of the biotechnology company’s stock worth $25,395,000 after acquiring an additional 218,869 shares during the last quarter. Hedge funds and other institutional investors own 56.87% of the company’s stock.

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: What are no-load funds?

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.